There are several advantages of targeting GOAT for the treatment of obesity, such as the selectivity to the targeted acylated ghrelin molecule, the uninterrupted constitutive activity of GHSR-1a (presumably necessary for appropriate growth hormone secretion) and the up regulation of unacylated ghrelin (UAG). Here, GHRL is linked to obesity due to melanocortin 4 receptor deficiency.